Trials / Completed
CompletedNCT06100900
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
An Open-Label, Multicenter, Intra-Subject Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential of BCX10013 in Subjects with Paroxysmal Nocturnal Hemoglobinuria
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with PNH. Approximately 8 participants will be enrolled in this study. Participants may receive treatment for up to 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCX10013 | Multiple dose levels may be tested in this study. |
Timeline
- Start date
- 2023-10-24
- Primary completion
- 2024-12-11
- Completion
- 2024-12-11
- First posted
- 2023-10-25
- Last updated
- 2025-01-08
Locations
4 sites across 2 countries: Malaysia, South Africa
Source: ClinicalTrials.gov record NCT06100900. Inclusion in this directory is not an endorsement.